Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatitis C, Chronic: early-phase trial registry
1 of 27 indexed Hepatitis C, Chronic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 1 currently recruiting · #598 of 28,707 conditions by registered trial count
Hepatitis C, Chronic: 27 US clinical trials tracked, 1 recruiting.
Hepatitis C, Chronic is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 9 of these trials.
Enrollment posture brief
Registry condition hepatitis-c-chronic
OPEN 1 | RECR 4% | LATE 8 | EARLY 15 | RANK #598 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Recurrent Melanoma (4% recruiting · 25 trials)
Hepatitis C, Chronic lists 1 open slots (4% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatitis C, Chronic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatitis C, Chronic is recruiting below its size-band peers.
1 of 27 indexed trials (3.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hepatitis C, Chronic research.
Hoffmann-La Roche accounts for 9 of 27 trials (33.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatitis C, Chronic enrolment sits around 115 participants.
Median target enrolment is 115 among the 27 trials that report a genuine target (sentinel values excluded). 10 of those (37%) plan for fewer than 100 participants.
-
Hepatitis C, Chronic research is mostly interventional.
25 interventional and 2 observational studies make up this index (92.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Catherine Anne Chappell
NCT05140941
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03520660
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Hoffmann-La Roche
NCT01675427
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
Tibotec BVBA
NCT00703118
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Gilead Sciences
NCT01457768
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Hoffmann-La Roche
NCT01220947
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
Hoffmann-La Roche
NCT00869661
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Gilead Sciences
NCT01356160
Dose Ranging of GSK2336805 in Combination Therapy
GlaxoSmithKline
NCT01648140
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Atea Pharmaceuticals
NCT05904470
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
Gilead Sciences
NCT01435044
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
Hoffmann-La Roche
NCT00623428
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
Conatus Pharmaceuticals
NCT00088140
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
Hoffmann-La Roche
NCT00077649
PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.
Hoffmann-La Roche
NCT00087633
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
Hoffmann-La Roche
NCT01628094
Anticipated and Perceived Benefits Following Hepatitis C Treatment
University of North Carolina, Chapel Hill
NCT03000023
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
Boehringer Ingelheim
NCT00793793
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00718172
Linkage to Care for Persons with Hep C Infection
Carilion Clinic
NCT05397067
SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C
GlaxoSmithKline
NCT00110799
A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
Hoffmann-La Roche
NCT02864199
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
ZymoGenetics
NCT00565539
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
HepQuant
NCT01579162
IdB 1016 Treatment for Hepatitis C Disease
National Center for Complementary and Integrative Health (NCCIH)
NCT00055445
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Hoffmann-La Roche
NCT01483742
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01888900
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 11 |
| Phase 3 | 2 |
| Phase 4 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatitis C, Chronic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatitis C, Chronic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatitis C, Chronic page
27 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Hepatitis C, Chronic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Hepatitis C, Chronic trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatitis C, Chronic condition card totals 27 registered trials; most-linked intervention Ribavirin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.